Industrial internationalization of the fully integrated “R&D-Manufacturing-Commercialization” value chain, establish a hub for innovative drugs to enter emerging overseas markets

Emerging markets such as Southeast Asia and the Middle East are rapidly unlocking pharmaceutical demand, driven by large populations, the expansion of the middle class, early-stage aging, improved healthcare infrastructure, and a rising burden of chronic diseases. These regions are becoming new growth engines for the global pharmaceutical industry. The Group is implementing an “industrial internationalization” strategy, with Singapore as its hub for Asia-Pacific emerging markets, building a fully integrated pharmaceutical ecosystem covering R&D, manufacturing, and commercialization. By channeling its rich portfolio of differentiated products and mature commercialization capabilities into these markets, the Group is enhancing access to medicines. On July 15, 2025, the Group achieved a secondary listing on the Singapore Exchange, further strengthening its collaborative platform in the Asia-Pacific region and advancing local healthcare accessibility.

Main Marketed Products

EyeOP1 Glaucoma Treatment Device (exclusive product)

Indication
Glaucoma with intraocular pressure that cannot be controlled by drugs and surgery

 

Combizym (Oryz-aspergillus Enzyme and Pancreatin Tablets) (exclusive product)

Indication
Dyspepsia caused by a decrease in digestive enzymes

The information on this page is only for the introduction of the medicines and medical devices to partners or medical professionals, not for product advertising. The product information on this website shall not replace medical advice and medical consultation provided by doctors or other qualified medical professionals, and shall not be used for disease diagnosis. For detailed information about the medicines and medical devices, please refer to the latest product instructions. If you have understood and confirmed the above content, please click OK to enter.